Literature DB >> 19996287

Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer.

Ping-Ying Pan1, Ge Ma, Kaare J Weber, Junko Ozao-Choy, George Wang, Bingjiao Yin, Celia M Divino, Shu-Hsia Chen.   

Abstract

Immune tolerance to tumors is often associated with accumulation of myeloid-derived suppressor cells (MDSC) and an increase in the number of T-regulatory cells (Treg). In tumor-bearing mice, MDSCs can themselves facilitate the generation of tumor-specific Tregs. In this study, we demonstrate that expression of the immune stimulatory receptor CD40 on MDSCs is required to induce T-cell tolerance and Treg accumulation. In an immune reconstitution model, adoptive transfer of Gr-1+CD115+ monocytic MDSCs derived from CD40-deficient mice failed to recapitulate the ability of wild-type MDSCs to induce tolerance and Treg development in vivo. Agonistic anti-CD40 antibodies phenocopied the effect of CD40 deficiency and also improved the therapeutic efficacy of IL-12 and 4-1BB immunotherapy in the treatment of advanced tumors. Our findings suggest that CD40 is essential not only for MDSC-mediated immune suppression but also for tumor-specific Treg expansion. Blockade of CD40-CD40L interaction between MDSC and Treg may provide a new strategy to ablate tumoral immune suppression and thereby heighten responses to immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996287      PMCID: PMC2805053          DOI: 10.1158/0008-5472.CAN-09-1882

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.

Authors:  Alessandra Mazzoni; Vincenzo Bronte; Alberto Visintin; Jessica H Spitzer; Elisa Apolloni; Paolo Serafini; Paola Zanovello; David M Segal
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

Review 2.  CD40/CD154 interactions at the interface of tolerance and immunity.

Authors:  Sergio A Quezada; Lamis Z Jarvinen; Evan F Lind; Randolph J Noelle
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

3.  A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory.

Authors:  Christine Bourgeois; Benedita Rocha; Corinne Tanchot
Journal:  Science       Date:  2002-09-20       Impact factor: 47.728

4.  Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease.

Authors:  Tetsuya Higuchi; Yuichi Aiba; Takashi Nomura; Junichiro Matsuda; Keiji Mochida; Misao Suzuki; Hitoshi Kikutani; Tasuku Honjo; Kiyoshi Nishioka; Takeshi Tsubata
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

5.  Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation.

Authors:  S A Kusmartsev; Y Li; S H Chen
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

6.  Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.

Authors:  J Schmielau; O J Finn
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 7.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  J Leukoc Biol       Date:  2003-08       Impact factor: 4.962

9.  IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.

Authors:  Vincenzo Bronte; Paolo Serafini; Carmela De Santo; Ilaria Marigo; Valeria Tosello; Alessandra Mazzoni; David M Segal; Caroline Staib; Marianne Lowel; Gerd Sutter; Mario P Colombo; Paola Zanovello
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

10.  Role of immature myeloid Gr-1+ cells in the development of antitumor immunity.

Authors:  Qingsheng Li; Ping-Ying Pan; Peidi Gu; Dongping Xu; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

View more
  180 in total

Review 1.  Myeloid-derived suppressor cells in transplantation and cancer.

Authors:  Jordi C Ochando; Shu Hsia Chen
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

2.  TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis.

Authors:  Liliana Guedez; Sandra Jensen-Taubman; Dimitra Bourboulia; Clifford J Kwityn; Beiyang Wei; John Caterina; William G Stetler-Stevenson
Journal:  J Immunother       Date:  2012-07       Impact factor: 4.456

Review 3.  Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Semin Cancer Biol       Date:  2012-01-31       Impact factor: 15.707

Review 4.  Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha; Daniel W Beury; Virginia K Clements
Journal:  Semin Cancer Biol       Date:  2012-02-01       Impact factor: 15.707

5.  Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease.

Authors:  Anja Wegner; Johan Verhagen; David C Wraith
Journal:  Immunology       Date:  2017-03-02       Impact factor: 7.397

6.  Recipient myeloid-derived immunomodulatory cells induce PD-1 ligand-dependent donor CD4+Foxp3+ regulatory T cell proliferation and donor-recipient immune tolerance after murine nonmyeloablative bone marrow transplantation.

Authors:  Marie van der Merwe; Hossam A Abdelsamed; Aman Seth; Taren Ong; Peter Vogel; Asha B Pillai
Journal:  J Immunol       Date:  2013-11-04       Impact factor: 5.422

7.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome.

Authors:  Juan C Mira; Lori F Gentile; Brittany J Mathias; Philip A Efron; Scott C Brakenridge; Alicia M Mohr; Frederick A Moore; Lyle L Moldawer
Journal:  Crit Care Med       Date:  2017-02       Impact factor: 7.598

8.  Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.

Authors:  Yong Wang; Cara C Schafer; Kenneth P Hough; Sultan Tousif; Steven R Duncan; John F Kearney; Selvarangan Ponnazhagan; Hui-Chen Hsu; Jessy S Deshane
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

9.  Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells.

Authors:  Catalina Lee-Chang; Monica Bodogai; Alejandro Martin-Montalvo; Katarzyna Wejksza; Mitesh Sanghvi; Ruin Moaddel; Rafael de Cabo; Arya Biragyn
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

10.  Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression.

Authors:  Maureen L Drakes; Patrick J Stiff
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.